Nicorette

(redirected from Habitrol)

Nicorette

(nĭk′ə-rĕt′)
A trademark for an over-the-counter preparation of chewing gum containing nicotine, used to treat nicotine dependence.

Nicorette

a trademark for a nicotine resin complex (nicotine polacrilex).

Nicorette®

See Nicotine gum.

Nicorette

A brand name for under-the-tongue tablets, chewing gum or artificial cigarettes containing NICOTINE. This is intended to make the abandonment of cigarette smoking a less painful procedure. Such measures are no real substitute for simple resolution and the acceptance of a brief period of suffering.
References in periodicals archive ?
Although GlaxoSmithKline had the potential to further boost its position in NRT, the FTC required that Novartis divest its Habitrol brand of NRT patches before the consumer health joint venture could be completed.
Reddy's Laboratories acquires Habitrol Brand from Novartis
5% interest in the joint venture, and without the divestitures required by the proposed order it would continue to own the Habitrol business, which had U.
At presently, GSK has its own nicotine replacement patch, Nicoderm CQ, a direct competitor of Habitrol.
27 November 2014 - Swiss healthcare group Novartis AG (VTX:NOVN) has agreed to offload its nicotine patch unit, Habitrol, to obtain clearance by the Federal Trade Commission (FTC) for its joint venture with UK peer GlaxoSmithKline plc (LON:GSK), the regulator said.
The contest is funded by the Government of Ontario with prize support provided by the makers of Thrive and Habitrol quit-smoking aids.
2) Transdermal patch formulation previously marketed as Habitrol.
There's the V-Chip, the Habitrol nicotine patch, an electronic hearing implant, and Google.
The plaintiff's federal appellate brief in a Habitrol case where the Oklahoma trial court held that that an exception to the learned intermediary rule exists where the FDA requires direct consumer warnings on prescription products.
The Institute for Safe Medication Practices (ISMP) issued the warning in the wake of an incident involving a patient who entered a MR scanner wearing a Habitrol smoking-cessation patch.
TABLE Transdermal Patch Comparison Dosage Trade Names Dosing Forms Available Habitrol 21 mg/day for 4 weeks, then 7,14, and 21 14 mg/day for 2 weeks, then mg/day patches 7 mg/day for 2 weeks Nicoderm, 21 mg/day for 6 weeks, then 7, 14, and 21 Nicoderm CQ 14 mg/day for 2 weeks, then mg/day patches Clear Nicoderm 7 mg/day for 2 weeks CQ Nicotrol 15 mg/16 hrs for 6 weeks 15 mg/16 hrs patch
Following the plaintiff's reasoning, the Oklahoma Supreme Court held that the FDA mandate of a direct patient warning created an exception to the learned intermediary doctrine, and imposed a common law duty on the Habitrol manufacturer to provide an adequate warning to the patient directly.